Press releases
- Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer
- Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update
- Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®
- Rigel Pharmaceuticals Provides Business Update
- Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Rigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in Glioma
- Rigel to Present at the 42nd Annual J.P. Morgan Healthcare Conference
More ▼
Key statistics
As of last trade Rigel Pharmaceuticals Inc (RI2A:BER) traded at 1.36, -24.05% below its 52-week high of 1.79, set on May 18, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.36 |
---|---|
High | 1.38 |
Low | 1.34 |
Bid | 1.32 |
Offer | 1.41 |
Previous close | 1.37 |
Average volume | 0.00 |
---|---|
Shares outstanding | 175.38m |
Free float | 171.76m |
P/E (TTM) | -- |
Market cap | 261.31m USD |
EPS (TTM) | -0.1444 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 19:30 BST.
More ▼